-

2022 Outlook on Digestive Remedies in the United States: Size and Shape of the Market - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Digestive Remedies in the US" report has been added to ResearchAndMarkets.com's offering.

Two years after the recall of ranitidine due to claims of increased risk of cancer, the H2 blockers category has continued to be impacted in 2022, as litigations have been in the public eye.

It is predicted that GSK, Sanofi and Pfizer could pay billions each in potential settlements, therefore increasing consumer awareness, and demand for transparency on ingredients and secondary effects. This is set to drive retail volume and current value decline in H2 blockers in 2022.

The Digestive Remedies in USA report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.

Product coverage: Diarrhoeal Remedies, IBS Treatments, Indigestion and Heartburn Remedies, Laxatives, Motion Sickness Remedies, Paediatric Digestive Remedies.

Data coverage: Market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

  • Get a detailed picture of the Digestive Remedies market;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market's major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.

Key Topics Covered:

DIGESTIVE REMEDIES IN THE US

KEY DATA FINDINGS

2022 DEVELOPMENTS

  • H2 blockers continues to suffer from ranitidine recall
  • Rethinking the relationship with food, and tracking changing consumer demand
  • Paediatric products gain traction as dietary concerns increase

PROSPECTS AND OPPORTUNITIES

  • Dulcolax leans into the popular trends of fruity products and chewable formats
  • Wonderbelly looks to shake up antacids with a trendily packaged, non-GMO, and plastic-free product

Mini capsules of omeprazole to enter OTC products in the US

CATEGORY DATA

  • Table 1 Sales of Digestive Remedies by Category: Value 2017-2022
  • Table 2 Sales of Digestive Remedies by Category: % Value Growth 2017-2022
  • Table 3 NBO Company Shares of Digestive Remedies: % Value 2018-2022
  • Table 4 LBN Brand Shares of Digestive Remedies: % Value 2019-2022
  • Table 5 Forecast Sales of Digestive Remedies by Category: Value 2022-2027
  • Table 6 Forecast Sales of Digestive Remedies by Category: % Value Growth 2022-2027

CONSUMER HEALTH IN THE US

EXECUTIVE SUMMARY

  • Consumer health in 2022: The big picture
  • 2022 key trends
  • Competitive landscape
  • Retailing developments
  • What next for consumer health?

MARKET INDICATORS

  • Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022
  • Table 8 Life Expectancy at Birth 2017-2022

MARKET DATA

  • Table 9 Sales of Consumer Health by Category: Value 2017-2022
  • Table 10 Sales of Consumer Health by Category: % Value Growth 2017-2022
  • Table 11 NBO Company Shares of Consumer Health: % Value 2018-2022
  • Table 12 LBN Brand Shares of Consumer Health: % Value 2019-2022
  • Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022
  • Table 14 Distribution of Consumer Health by Format: % Value 2017-2022
  • Table 15 Distribution of Consumer Health by Format and Category: % Value 2022
  • Table 16 Forecast Sales of Consumer Health by Category: Value 2022-2027
  • Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027

For more information about this report visit https://www.researchandmarkets.com/r/5t3ddf

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Blockchain and Non-Fungible Tokens new Technologies and the Relevant Law Training Course: Core Principles, Smart Contracts, NFTs, and Decentralized Finance Explained (Online Event: May 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Blockchain and Non-Fungible Tokens: Understanding new Technologies and the Relevant Law Training Course (May 20, 2026)" training has been added to ResearchAndMarkets.com's offering. Blockchain is a new technology that could potentially have major impacts in a wide range of industries. It has the potential to dramatically change how business is conducted - but there is no one central authority controlling blockchain, everyone has access to the same information. Are...

Writing Clinical Research with Integrity Training Course: Principles of Medical and Scientific Writing, Including Ethical Standards, Data Integrity, and Plagiarism Prevention (Online: Apr 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Writing Clinical Research with Integrity Training Course (Apr 20, 2026)" training has been added to ResearchAndMarkets.com's offering. This course covers key principles of medical and scientific writing, including ethical standards, data integrity, and plagiarism prevention. Participants will learn how to tailor content for various audiences, structure documents (e.g., manuscripts, protocols), and adhere to writing standards such as clarity, consistency, and correc...

In-Vitro Diagnostic Regulation (EU) 2017/746 Introduction Training Course (Online Event: Apr 16th - Apr 17th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Introduction to the In-Vitro Diagnostic Regulation (IVDR) Training Course (Apr 16th - Apr 17th, 2026)" training has been added to ResearchAndMarkets.com's offering. The In-Vitro Diagnostic Regulation (EU) 2017/746, which came into force in May 2017 with a transition period of five years, is intended to strengthen the current approval system for in-vitro diagnostics and makes substantial changes to the existing IVD Directive (98/79/EC) legislation. The Regulation in...
Back to Newsroom